DK2421895T3 - Rekombinant human alfa1-antitrypsin - Google Patents
Rekombinant human alfa1-antitrypsin Download PDFInfo
- Publication number
- DK2421895T3 DK2421895T3 DK10716318.0T DK10716318T DK2421895T3 DK 2421895 T3 DK2421895 T3 DK 2421895T3 DK 10716318 T DK10716318 T DK 10716318T DK 2421895 T3 DK2421895 T3 DK 2421895T3
- Authority
- DK
- Denmark
- Prior art keywords
- glycans
- rhaat
- per
- aat
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (14)
1.
Rekombinant human αΐ-antitrypsin (rhAAT) , der omfatter tilkoblede glycaner, der er kendetegnet ved, at: (a) mindst 10 % af de N-koblede glycaner er tetraantenne-glycaner; og (b) graden af capping med sialinsyre på de N-koblede glycaner (Z/A) er mindst 50 %, hvor mindst 50 % af den totale sialylering på de N-koblede glycaner er a-2,3-sialylering.
2.
rhAAT ifølge krav 1, hvor mindst 20 % af de N-koblede glycaner er tetraantenne-glycaner.
3.
rhAAT ifølge krav 1 eller 2, hvor fra ca.
10 % til 50 % af de N-koblede glycaner er tetraantenne-glycaner.
4.
rhAAT ifølge krav 1 eller 2, hvor fra ca.
20 % til 40 % af de N-koblede glycaner er tetraantenne-glycaner.
5.
rhAAT ifølge et hvilket som helst af ovennævnte krav, hvor mindst 90 % af den totale sialylering på de N-koblede glycaner er a-2,3-sialylering. 6. rhAAT ifølge et hvilket som helst af ovennævnte krav, hvor graden af capping med sialinsyre på de N-koblede glycaner (beregnet ved hjælp af Z/A-forholdet) er mindst 70 %, fortrinsvis mindst 80 %, mere fortrinsvis mindst 90 %. 7. rhAAT ifølge et hvilket som helst af ovennævnte krav, hvor graden af capping med sialinsyre på de N-koblede glycaner, der er tetraantenne-glycaner, er mindst 20 %. 8. rhAAT ifølge et hvilket som helst af ovennævnte krav, hvor graden af capping med sialinsyre på de N-koblede glycaner, der er tetraantenne-glycaner, er mindst 50 %. 9. rhAAT ifølge krav 8, hvor graden af capping med sialinsyre på de N-koblede glycaner, der er tetraantenne-glycaner, er fra ca. 50 % til ca. 97 %. 10. rhAAT ifølge et hvilket som helst af ovennævnte krav, hvor graden af capping med sialinsyre på de N-koblede glycaner, der er tetraantenne-glycaner, er fra ca. 70 % til ca. 95 %. 11. rhAAT ifølge et hvilket som helst af ovennævnte krav til anvendelse som et medikament. 12. rhAAT ifølge et hvilket som helst af ovennævnte krav til anvendelse til forebyggelse og/eller behandling af en sygdom, der er forbundet med AAT-deficiens, og/eller en sygdom, der medfører neutrofilmedieret vævsskade.
13.
Fremgangsmåde til fremstilling af rekombinant human al-antitrypsin (rhAAT) ifølge krav 1, der omfatter trinene tilvejebringelse af en PER.C6-celle med en nukleinsyre, der koder for human αΐ-antitrypsin på en sådan måde, at PER.C6-cellen huser nukleinsyren i en udtrykkelig form; og dyrkning af PER.C6-cellen under betingelser, der er fremmende for produktionen af den rekombinante humane αΐ-antitrypsin, hvor PER.C6-cellen er modificeret til co-ekspression af en cx2,3-sialyltransferase. 14. rhAAT ifølge krav 1, der kan opnås ved hjælp af en fremgangsmåde ifølge krav 13.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21449209P | 2009-04-23 | 2009-04-23 | |
| EP09158640 | 2009-04-23 | ||
| PCT/EP2010/055177 WO2010127939A1 (en) | 2009-04-23 | 2010-04-20 | Recombinant human alpha1-antitrypsin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2421895T3 true DK2421895T3 (da) | 2016-01-25 |
Family
ID=40929544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10716318.0T DK2421895T3 (da) | 2009-04-23 | 2010-04-20 | Rekombinant human alfa1-antitrypsin |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8357661B2 (da) |
| EP (1) | EP2421895B1 (da) |
| JP (1) | JP5711215B2 (da) |
| KR (1) | KR101640962B1 (da) |
| CN (1) | CN102439037B (da) |
| AU (1) | AU2010244592B2 (da) |
| CA (1) | CA2756591C (da) |
| DK (1) | DK2421895T3 (da) |
| EA (1) | EA025021B1 (da) |
| ES (1) | ES2559007T3 (da) |
| IL (1) | IL215537A (da) |
| PL (1) | PL2421895T3 (da) |
| WO (1) | WO2010127939A1 (da) |
| ZA (1) | ZA201107416B (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2756591C (en) | 2009-04-23 | 2018-11-06 | Crucell Holland B.V. | Recombinant human alpha1-antitrypsin |
| KR20140132706A (ko) * | 2011-12-19 | 2014-11-18 | 엘에프비 유에스에이, 인크. | 염증성 장애의 치료를 위한 재조합 인간 알파-1-안티트립신 |
| US9353165B2 (en) | 2012-07-25 | 2016-05-31 | Grifols, S.A. | Purification of cell culture derived alpha1 protease inhibitor |
| CN102994514B (zh) * | 2012-11-07 | 2015-06-10 | 武汉禾元生物科技股份有限公司 | 一种从水稻种子生产和分离纯化重组人抗胰蛋白酶(OsrAAT)的方法 |
| CN105263319A (zh) | 2013-02-13 | 2016-01-20 | 法国化学与生物科技实验室 | 具有经修饰的糖基化的蛋白及其生产方法 |
| EP3205719A1 (en) * | 2016-02-15 | 2017-08-16 | CEVEC Pharmaceuticals GmbH | Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins |
| EP3382014A1 (en) * | 2017-03-29 | 2018-10-03 | CEVEC Pharmaceuticals GmbH | Recombinant glycoproteins with reduced antennary fucosylation |
| WO2018183705A1 (en) | 2017-03-29 | 2018-10-04 | Cornell University | Oxidation-resistant aat gene therapy |
| EP3441471A1 (en) | 2017-08-08 | 2019-02-13 | CEVEC Pharmaceuticals GmbH | Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines |
| EP3717640A1 (en) | 2017-11-28 | 2020-10-07 | Danmarks Tekniske Universitet | Glycosylation of proteins |
| CA3127750A1 (en) * | 2019-01-24 | 2020-07-30 | Excellgene Sa | Methods of producing and using recombinant alpha 1-antitrypsin (aat) and compositions thereof |
| WO2024075112A1 (en) * | 2022-10-06 | 2024-04-11 | Kamada Ltd. | Highly fucosylated recombinant human alpha 1 antitrypsin (aat) protein having immunomodulatory activity and compositions comprising the same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0833934T4 (da) | 1995-06-15 | 2012-11-19 | Crucell Holland Bv | Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi |
| WO2003048348A2 (en) * | 2001-12-07 | 2003-06-12 | Crucell Holland B.V. | Production of viruses, viral isolates and vaccines |
| PT1161548E (pt) | 1999-04-15 | 2005-06-30 | Crucell Holland Bv | Producao de proteinas recombinantes numa celula humana utilizando sequencias codificando a proteina e1 de adenovirus |
| US7297680B2 (en) * | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
| US20050164386A1 (en) | 1999-04-15 | 2005-07-28 | Uytdehaag Alphonsus G. | Overexpression of enzymes involved in post-translational protein modifications in human cells |
| EA008670B1 (ru) | 2003-05-09 | 2007-06-29 | Круселл Холланд Б.В. | Культуры e1-иммортализованных клеток и способы их культивирования с целью повышения выхода их продукции |
| CN101090973B (zh) * | 2004-12-30 | 2012-03-28 | 克鲁塞尔荷兰公司 | 从表达腺病毒e1a蛋白的细胞中获得唾液酸化增加的重组蛋白质的方法及由此获得的蛋白质 |
| WO2007102432A1 (ja) * | 2006-03-02 | 2007-09-13 | Kyowa Hakko Kogyo Co., Ltd. | 糖蛋白質組成物の製造方法 |
| WO2008069244A1 (ja) * | 2006-12-05 | 2008-06-12 | Kyowa Hakko Kogyo Co., Ltd. | 糖蛋白質組成物の製造方法 |
| KR101510778B1 (ko) * | 2007-07-12 | 2015-04-10 | 상가모 바이오사이언스 인코포레이티드 | 알파 1,6 당전이효소(ｆｕｔ8) 유전자 발현을 비활성화시키기 위한 방법 및 조성물 |
| CA2756591C (en) | 2009-04-23 | 2018-11-06 | Crucell Holland B.V. | Recombinant human alpha1-antitrypsin |
-
2010
- 2010-04-20 CA CA2756591A patent/CA2756591C/en active Active
- 2010-04-20 PL PL10716318T patent/PL2421895T3/pl unknown
- 2010-04-20 DK DK10716318.0T patent/DK2421895T3/da active
- 2010-04-20 EA EA201171275A patent/EA025021B1/ru not_active IP Right Cessation
- 2010-04-20 CN CN201080017593.2A patent/CN102439037B/zh active Active
- 2010-04-20 US US13/138,912 patent/US8357661B2/en active Active
- 2010-04-20 ES ES10716318.0T patent/ES2559007T3/es active Active
- 2010-04-20 WO PCT/EP2010/055177 patent/WO2010127939A1/en active Application Filing
- 2010-04-20 EP EP10716318.0A patent/EP2421895B1/en active Active
- 2010-04-20 KR KR1020117027863A patent/KR101640962B1/ko active IP Right Grant
- 2010-04-20 JP JP2012506465A patent/JP5711215B2/ja active Active
- 2010-04-20 AU AU2010244592A patent/AU2010244592B2/en active Active
-
2011
- 2011-10-04 IL IL215537A patent/IL215537A/en active IP Right Grant
- 2011-10-10 ZA ZA2011/07416A patent/ZA201107416B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102439037B (zh) | 2015-01-07 |
| IL215537A0 (en) | 2011-12-29 |
| WO2010127939A1 (en) | 2010-11-11 |
| US20120214747A1 (en) | 2012-08-23 |
| EA201171275A1 (ru) | 2012-03-30 |
| AU2010244592B2 (en) | 2016-05-19 |
| AU2010244592A1 (en) | 2011-10-27 |
| ZA201107416B (en) | 2017-11-29 |
| EP2421895A1 (en) | 2012-02-29 |
| CA2756591C (en) | 2018-11-06 |
| KR101640962B1 (ko) | 2016-07-19 |
| EP2421895B1 (en) | 2015-11-11 |
| ES2559007T3 (es) | 2016-02-10 |
| CA2756591A1 (en) | 2010-11-11 |
| KR20120096871A (ko) | 2012-08-31 |
| IL215537A (en) | 2016-06-30 |
| JP5711215B2 (ja) | 2015-04-30 |
| US8357661B2 (en) | 2013-01-22 |
| CN102439037A (zh) | 2012-05-02 |
| EA025021B1 (ru) | 2016-11-30 |
| PL2421895T3 (pl) | 2016-04-29 |
| JP2012524747A (ja) | 2012-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2421895T3 (da) | Rekombinant human alfa1-antitrypsin | |
| JP5685363B2 (ja) | グリコシル化されたｉｌ−７、調製及び使用 | |
| KR101582841B1 (ko) | 콘쥬게이트된 인자 ｖｉｉｉ 분자 | |
| EP2292770B1 (en) | Methods for producing proteins with predetermined post-translational modifications | |
| KR101319733B1 (ko) | 아데노바이러스 ｅ１ａ 단백질을 발현하는 세포로부터시알릴화가 증가된 재조합 단백질의 제조 방법, 및 그로인해 얻어진 단백질들 | |
| RU2453597C2 (ru) | Способ получения иммортализованной клетки человека, стабильно трансфицированная иммортализованная клетка человека, способ рекомбинантной продукции целевого белка человека, применение вектора трансфекции | |
| TWI835772B (zh) | Il-22fc融合蛋白及使用方法 | |
| TWI716340B (zh) | 具有ｘｔｅｎ之凝血酶可裂解連接子及其用途 | |
| EP2150561B1 (en) | Demannosylated recombinant factor VIII for the treatment of patients with haemophilia A | |
| JP2008120810A (ja) | 組織因子活性インヒビターｔｆｐｉおよびｔｆｐｉ−２のキメラタンパク質および変異体 | |
| AU2002335585A1 (en) | Methods and means for producing proteins with predetermined post-translational modifications | |
| TW201542596A (zh) | 凝血酶可裂解連接子 | |
| KR101402702B1 (ko) | 신규한 알파-1 안티트립신 변이체, 이의 제조방법 및 용도 | |
| Kido et al. | Cellular proteases involved in the pathogenicity of enveloped animal viruses, human immunodeficiency virus, influenza virus A and Sendai virus | |
| Ross et al. | Production and characterization of a novel human recombinant alpha-1-antitrypsin in PER. C6 cells | |
| US7642078B2 (en) | Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby | |
| BRPI1015341B1 (pt) | Alfa-1 antitripsina humana recombinante (rhaat) e método para produzir alfa-1 antitripsina humana recombinante (rhaat) | |
| US20100221774A1 (en) | Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby |